研究单位：[1]First Affiliated Hospital of Zhejiang University[2]Dizal Pharmaceuticals[3]Anhui Provincial Hospital (The First Affiliated Hospital of USTC),Hefei,Anhui,China[4]Peking university Third Hospital,Beijing,Beijing,China[5]Guangdong Provincial People''s Hospital,Guangzhou,Guangdong,China[6]Sun Yat-sen University Cancer Center,Guangzhou,Guangdong,China[7]The Fifth Affiliated Hospital of Sun Yat-sen University,Zhuhai,Guangdong,China[8]Hainan General Hospital,Haikou,Hainan,China[9]The Fourth Hospital of Hebei Medical University,Shijiazhuang,Hebei,China[10]Henan Cancer Hospital,Zhengzhou,Henan,China[11]Hubei Cancer Hospital,Wuhan,Hubei,China[12]Union Hospital Tongji Medical College Huazhong University of Science and Thechnology,Wuhan,Hubei,China[13]Hunan Cancer Hospital,Changsha,Hunan,China[14]Reasearch Center of Clinical Trials, The Third Xiangya Hospital of Central South University,Changsha,Hunan,China[15]The Affiliated Hospital of Inner Mongolia Medical University,Hohhot,Inner Mongolia,China[16]The Second Affiliated Hospital of Nanchang University,Nanchang,Jiangxi,China[17]Shandong Cancer Hospital & Insititution,Jinan,Shandong,China[18]Linyi Cancer Hospital,Linyi,Shandong,China[19]Shanxi Provincial Cancer Hospital,Taiyuan,Shanxi,China[20]West China Hospital of Sichuan University,Chengdu,Sichuan,China[21]Tianjin Medical University Cancer Institute & Hospital,Tianjin,Tianjin,China[22]Yunnan Cancer Hospital,Kunming,Yunan,China[23]The First Affiliated Hospital, College of Medicine, Zhejiang University,Hangzhou,Zhejiang,China
研究目的：
This study is intended to assess the safety and anti-tumor activity of AZD4205 at 150 mg once daily in participants with PTCL who have achieved tumor response after first-line systemic therapy (with or without combination radiotherapy) and are ineligible for HSCT assessed by the investigator as ineligible for HSCT or have no plan for HSCT.
